扶正化瘀方对肝癌患者MMP-3和ESM-1表达的影响
|
摘要
目的:探讨扶正化瘀方治疗原发性肝细胞癌(hepatocellular carcinoma,HCC)中基质金属蛋白酶(matrix metalloproteinase-3,MMP-3)和内皮细胞特异分子-1(endothelial cell specific molecule,ESM-1)的表达及其与患者疾病预后之间的关系。方法:治疗组收集78例HCC患者作为研究对象,并将同时期来本院治疗的60例肝癌患者作为对照组。测定两组MMP-3和ESM-1的表达情况,比较两组阳性率,并分析其扶正化瘀治疗与各病理参数间、MMP-3和ESM-1表达情况的关系及与患者预后的关系。结果:治疗组MMP-3和ESM-1阳性率分别为15.00%和5.00%,对照组阳性率分别为71.79%和76.92%,两组比较,差异有统计学意义(P<0.05)。治疗组MMP-3和ESM-1表达与对照组TNM分期、分化程度和门静脉癌栓有显著差异(P<0.05)。对照组MMP-3和ESM-1患者生存时间和生存率低于治疗组(P<0.01)。结论:治疗组患者MMP-3和ESM-1阳性率显著低于对照组,两组各个TNM分期、分化程度和门静脉癌栓比较有差异。扶正化瘀方可以降低HCC的恶性程度,MMP-3和ESM-1可以作为评估扶正化瘀方治疗HCC患者预后的一项重要指标。
Objective:To investigate the expression of matrix metalloproteinase-3(MMP-3) and endothelial cell specific molecule-1(ESM-1) in primary hepatocellular carcinoma(HCC) treated with Fuzheng Huayu Decoction and their relationship with prognosis of patients with HCC.Methods:The treatment group collected 78 cases of HCC patients as the research object,and 60 cases of HCC patients who came to our hospital for other treatment at the same time as the control group.The expression of MMP-3 and ESM-1 in the two groups were measured,and the positive rates were compared.The relationship between the treatment of strengthening the body and removing blood stasis and the pathological parameters,the expression of MMP-3 and ESM-1 and the prognosis of the patients were analyzed.Results:The positive rates of MMP-3 and ESM-1 were 15.00% and 5.00% in the treatment group and 71.79% and 76.92% in the control group,respectively.There was a significant difference between the two groups(P<0.05).The expression of MMP-3 and ESM-1 in Fuzheng Huayu treatment group was significantly different from that in control group in TNM stage,differentiation degree and portal vein cancer thrombus(P<0.05).The survival time and survival rate of MMP-3 and ESM-1 patients in the control group were lower than those in the Fuzheng Huayu treatment group(P<0.01).Conclusion:The positive rates of MMP-3 and ESM-1 in the Fuzheng Huayu treatment group were significantly lower than those in the control group.There were differences between the two groups in TNM stage,differentiation degree and portal vein cancer thrombus.Fuzheng Huayu Decoction can reduce the malignant degree of HCC.MMP-3 and ESM-1 can be used as an important index to evaluate the prognosis of patients with HCC treated by Fuzheng Huayu Decoction.
Objective:To investigate the expression of matrix metalloproteinase-3(MMP-3) and endothelial cell specific molecule-1(ESM-1) in primary hepatocellular carcinoma(HCC) treated with Fuzheng Huayu Decoction and their relationship with prognosis of patients with HCC.Methods:The treatment group collected 78 cases of HCC patients as the research object,and 60 cases of HCC patients who came to our hospital for other treatment at the same time as the control group.The expression of MMP-3 and ESM-1 in the two groups were measured,and the positive rates were compared.The relationship between the treatment of strengthening the body and removing blood stasis and the pathological parameters,the expression of MMP-3 and ESM-1 and the prognosis of the patients were analyzed.Results:The positive rates of MMP-3 and ESM-1 were 15.00% and 5.00% in the treatment group and 71.79% and 76.92% in the control group,respectively.There was a significant difference between the two groups(P<0.05).The expression of MMP-3 and ESM-1 in Fuzheng Huayu treatment group was significantly different from that in control group in TNM stage,differentiation degree and portal vein cancer thrombus(P<0.05).The survival time and survival rate of MMP-3 and ESM-1 patients in the control group were lower than those in the Fuzheng Huayu treatment group(P<0.01).Conclusion:The positive rates of MMP-3 and ESM-1 in the Fuzheng Huayu treatment group were significantly lower than those in the control group.There were differences between the two groups in TNM stage,differentiation degree and portal vein cancer thrombus.Fuzheng Huayu Decoction can reduce the malignant degree of HCC.MMP-3 and ESM-1 can be used as an important index to evaluate the prognosis of patients with HCC treated by Fuzheng Huayu Decoction.
引文
[1]CHENG Z,LI X F,DING J.Characteristics of liver cancer stem cells and clinical correlations[J].Cancer Letters,2016,379:230-238.
[2]TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65:87-108.
[3]仵志远,姜德清,郝占伟.CD147和基质金属蛋白酶-9在肝细胞肝癌中的表达与微血管生成的相关性[J].蚌埠医学院学报,2015,40(4):450-452.
[4]MORISEZ,KAWABE N,TOMISHIGE H,et al.Recent advances in the surgical treatment of hepatocellular carcinoma[J].World J Gastroenterol,2014,20:14381-14392.
[5]MALUCCIO M,COVEY A.Recent progress in understanding,diagnosing,and treating hepatocellular carcinoma[J].CA Cancer J Clin,2012,62:394-399.
[6]BRUIX J,SHERMAN M.American Association for the Study of Liver Diseases,Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53:1020-1022.
[7]贺军,丁成明,贺更生,等.ESM-1和MMP-3表达与肝癌侵袭转移的关系[J].中南医学科学杂志,2012,40(4):368-372.
[8]LASSALLE P,MOLET S,JANIN A,et al.ESM-1 is a novel human en-dothelial cell-specific molecule expressed in lung and regulated by cytokines[J].J Biol Chem,1996,271(34):20458-20464.
[9]龙驰,张濛,张明慧,等.内皮细胞特异分子-1与人类肿瘤关系的研究进展[J].现代肿瘤医学,2013,21(5):1162-1166.
[10]DERYUGINA E I,QUIGLEY J P.Matrix metalloproteinases and tumor metastasis [J].Cancer and Metastasis Rev,2006,25(1):9-34.
[11]BLUMENSON L E,BROSS I D.A possible mechanism for enhancement of increased production of tumor angiogenic factor[J].Growth,1976,40(3):205-209.
[12]嵇学仙,陈秋强,石麒麟,等.非小细胞肺癌MMP-3和TIMP-3表达与间质微血管密度和肿瘤转移的关系[J].肿瘤学杂志,2012,18(3):185-188.
[13]肖敏,黄孙卉.MMP-3和p53蛋白在乳腺癌组织中的表达及其与肿瘤转移的关系[J].实用肿瘤学杂志,2008,22(6):514-516.
[14]李春龙,崔云甫,杜雪飞,等.MMP-3和VEGF在胰腺癌中的表达及临床意义[J].世界华人消化杂志,2011,15(12):1574-1578.
[15]廖如奕,牛灵.基质金属蛋白酶-3和血管内皮生长因子在胃癌组织中的表达及意义[J].肿瘤防治研究,2011,38(10):1140-1142.
[16]刘从云,吴正升,张晴,等.乳腺癌组织中 ESM-1 的表达及其预后意义[J].安徽医科大学学报,2008,43(4):391-394.
[17]LIU N,ZHANG LH,DU H,et al.Over-expression of endothelial cell specific molecule-1(ESM-1) in gastric cancer[J].Ann Surg Oncol,2010,17(10):2628-2639.
[18]LEROY X,AUBERT S,ZINI L,et al.Vascular endocan(ESM-1) is markedly over-expressed in clear cell renal cell carcinoma[J].Histopathology,2010,56(2):180-187.
[19]CARRILLO L M,ARCINIEGAS E,ROJAS H,et al.Immunolocalization of endocan during the endothelial-mesenchymal transition process [J].Eur J Histochem,2011,55(2):73-77.
[2]TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65:87-108.
[3]仵志远,姜德清,郝占伟.CD147和基质金属蛋白酶-9在肝细胞肝癌中的表达与微血管生成的相关性[J].蚌埠医学院学报,2015,40(4):450-452.
[4]MORISEZ,KAWABE N,TOMISHIGE H,et al.Recent advances in the surgical treatment of hepatocellular carcinoma[J].World J Gastroenterol,2014,20:14381-14392.
[5]MALUCCIO M,COVEY A.Recent progress in understanding,diagnosing,and treating hepatocellular carcinoma[J].CA Cancer J Clin,2012,62:394-399.
[6]BRUIX J,SHERMAN M.American Association for the Study of Liver Diseases,Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53:1020-1022.
[7]贺军,丁成明,贺更生,等.ESM-1和MMP-3表达与肝癌侵袭转移的关系[J].中南医学科学杂志,2012,40(4):368-372.
[8]LASSALLE P,MOLET S,JANIN A,et al.ESM-1 is a novel human en-dothelial cell-specific molecule expressed in lung and regulated by cytokines[J].J Biol Chem,1996,271(34):20458-20464.
[9]龙驰,张濛,张明慧,等.内皮细胞特异分子-1与人类肿瘤关系的研究进展[J].现代肿瘤医学,2013,21(5):1162-1166.
[10]DERYUGINA E I,QUIGLEY J P.Matrix metalloproteinases and tumor metastasis [J].Cancer and Metastasis Rev,2006,25(1):9-34.
[11]BLUMENSON L E,BROSS I D.A possible mechanism for enhancement of increased production of tumor angiogenic factor[J].Growth,1976,40(3):205-209.
[12]嵇学仙,陈秋强,石麒麟,等.非小细胞肺癌MMP-3和TIMP-3表达与间质微血管密度和肿瘤转移的关系[J].肿瘤学杂志,2012,18(3):185-188.
[13]肖敏,黄孙卉.MMP-3和p53蛋白在乳腺癌组织中的表达及其与肿瘤转移的关系[J].实用肿瘤学杂志,2008,22(6):514-516.
[14]李春龙,崔云甫,杜雪飞,等.MMP-3和VEGF在胰腺癌中的表达及临床意义[J].世界华人消化杂志,2011,15(12):1574-1578.
[15]廖如奕,牛灵.基质金属蛋白酶-3和血管内皮生长因子在胃癌组织中的表达及意义[J].肿瘤防治研究,2011,38(10):1140-1142.
[16]刘从云,吴正升,张晴,等.乳腺癌组织中 ESM-1 的表达及其预后意义[J].安徽医科大学学报,2008,43(4):391-394.
[17]LIU N,ZHANG LH,DU H,et al.Over-expression of endothelial cell specific molecule-1(ESM-1) in gastric cancer[J].Ann Surg Oncol,2010,17(10):2628-2639.
[18]LEROY X,AUBERT S,ZINI L,et al.Vascular endocan(ESM-1) is markedly over-expressed in clear cell renal cell carcinoma[J].Histopathology,2010,56(2):180-187.
[19]CARRILLO L M,ARCINIEGAS E,ROJAS H,et al.Immunolocalization of endocan during the endothelial-mesenchymal transition process [J].Eur J Histochem,2011,55(2):73-77.